These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12170508)

  • 1. [The SBU revises its view on estrogen replacement therapy in climacteric. Evidently increased risk of thrombosis and breast cancer].
    Hovelius B
    Lakartidningen; 2002 Jul; 99(28-29):3014-5. PubMed ID: 12170508
    [No Abstract]   [Full Text] [Related]  

  • 2. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
    Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Only two secure indications left. Changing one's view of hormone replacement therapy].
    Fath R
    Dtsch Med Wochenschr; 2003 Oct; 128(43):2236. PubMed ID: 14608994
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].
    Magnusson C; Weiderpass E
    Lakartidningen; 2001 Jan; 98(5):418-21. PubMed ID: 11229082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombophilic profile of climacteric and menopausal women with venous thromboembolism.
    Margarido PF; D'Amico E; Bagnoli VR; Fonseca AM; Halbe HW; Pinotti JA
    Climacteric; 2002 Mar; 5(1):87-9. PubMed ID: 11974563
    [No Abstract]   [Full Text] [Related]  

  • 6. [The storm around hormonal replacement therapy].
    Heikinheimo O; Kaaja R
    Duodecim; 2002; 118(18):1833-5. PubMed ID: 12422665
    [No Abstract]   [Full Text] [Related]  

  • 7. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C; Reeves G
    Lakartidningen; 2005 Apr 18-24; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract]   [Full Text] [Related]  

  • 8. [Estrogen therapy in climacteric. Current views in an evidence-based perspective].
    Nilsson K
    Lakartidningen; 2001 Jul; 98(28-29):3225-8. PubMed ID: 11496812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study.
    Rexrode KM; Manson JE
    Circulation; 2007 Feb; 115(7):820-2. PubMed ID: 17309929
    [No Abstract]   [Full Text] [Related]  

  • 10. HRT and venous thromboembolism: more evidence of a link.
    Chen BH
    CMAJ; 2001 Jan; 164(1):87. PubMed ID: 11202677
    [No Abstract]   [Full Text] [Related]  

  • 11. [Estrogen during and after climacteric--problems and possibilities for primary health care].
    Blivik J
    Lakartidningen; 2001 Mar; 98(10):1145-6. PubMed ID: 11301984
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term hormone replacement and risk of breast carcinoma: current status. On behalf of the German Menopause Society and the Professional Society of Gynecologic Endocrinology and Reproductive Medicine of the German Society of Gynecology and Obstetrics].
    Kuhl H; Runnebaum B; Schneider HP
    Zentralbl Gynakol; 1995; 117(10):549-53. PubMed ID: 7491838
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormone replacement therapy and thrombotic risk: beauty is only skin deep.
    Rosendaal FR
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):684-5. PubMed ID: 18797429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter by Micheletti and Chevallier regarding article, "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study".
    Micheletti MC; Chevallier T
    Circulation; 2007 Sep; 116(13):e362; author reply e363. PubMed ID: 17893283
    [No Abstract]   [Full Text] [Related]  

  • 16. Individualising hormone replacement therapy.
    Attilakos G; Wardle PG
    Practitioner; 2002 May; 246(1634):295-8, 302, 305 passim. PubMed ID: 12043347
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormone therapy and breast cancer risk.
    Foidart JM; Desreux J; Pintiaux A; Gompel A
    Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone therapy in postmenopausal and perimenopausal women.
    Magee SR; Taylor JS
    Am Fam Physician; 2006 Nov; 74(9):1501-3. PubMed ID: 17111886
    [No Abstract]   [Full Text] [Related]  

  • 19. Hormone therapy and thromboembolic disease.
    Battaglioli T; Martinelli I
    Curr Opin Hematol; 2007 Sep; 14(5):488-93. PubMed ID: 17934355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
    Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.